Molecular predictive biomarker testing in advanced thyroid cancer – a European consensus

DTC: comprehensive DNA and RNA next-generation sequencing (NGS) testing for patients whose disease has progressed on or is resistant to RAI

MTC: RET germline testing for all patients at diagnosis

MTC: for high-risk clinical or pathological features and progressive disease, somatic RET testing with NGS should be discussed and conducted before considering systemic treatment

ATC: molecular reflex testing for BRAF mutations for all patients at diagnosis, followed by DNA and RNA NGS for those BRAF negative

Recommendations on use of tumor tissue for testing and on centralization of molecular testing involving multidisciplinary tumor boards